Significant disproportionalities emerged also for transient ischemic attacks, cerebral ischemia, paraplegia, and paraparesis (Table S2), with a more rapid time to onset than other CDK4/6 inhibitors (1 vs. 6 months, respectively). The gene discussed is CDK4; the disease is paraplegia.